$3.96
0.174.49%
Last update: Oct 29, 6:50 AM
Aclaris Therapeutics Inc (ACRS) Stock Price, Quote, News & History
ACRSNASDAQ
Aclaris Therapeutics announces positive Phase 1b trial data for ATI-052 in eczema and asthma alongside a $50 million public financing round.
You can purchase shares of Aclaris Therapeutics (NASDAQ:ACRS) through any online brokerage.
Other companies in Aclaris Therapeutics’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Aclaris Therapeutics has a consensus price target of $9.62.
The stock price for Aclaris Therapeutics (NASDAQ: ACRS) is $4.01 last updated October 29, 2026 at 6:50 AM EDT.
There are no upcoming dividends for Aclaris Therapeutics.
Aclaris Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Aclaris Therapeutics.
Aclaris Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the...
